Vor Biopharma Inc. Board of Directors

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Dr. Eyal C. Attar M.D.

Dr. Eyal C. Attar M.D.

Chief Medical Officer

Mr. David Phillips M.B.A.

Mr. David Phillips M.B.A.

Senior VP & Head of Quality

Ms. Amy Quinlan

Ms. Amy Quinlan

Interim Principal Accounting Officer

Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.

Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.

Scientific Founder & Chairman of Scientific Advisory Board

Mr. John C. King M.B.A.

Mr. John C. King M.B.A.

Chief Commercial Officer & Head of Business Development

Ms. Tania Philipp

Ms. Tania Philipp

Chief People Officer

Dr. Han Choi M.D.

Dr. Han Choi M.D.

Chief Financial Officer

Dr. Tirtha Chakraborty Ph.D.

Dr. Tirtha Chakraborty Ph.D.

Chief Scientific Officer

Mr. Samir Vattompadam M.S.

Mr. Samir Vattompadam M.S.

Senior Vice President of Portfolio Strategy & Program Management

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.